Published in Clin Cancer Res on January 01, 2005
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol (2009) 2.35
The genetics of osteosarcoma. Sarcoma (2012) 1.33
A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res (2009) 1.24
A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene (2009) 1.14
Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. J Clin Invest (2013) 1.13
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro Oncol (2013) 1.11
Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch (2014) 1.09
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. J Exp Clin Cancer Res (2014) 1.08
Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol (2013) 1.07
Alternative lengthening of telomeres in normal mammalian somatic cells. Genes Dev (2013) 1.04
Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. PLoS One (2012) 1.04
Induction of alternative lengthening of telomeres-associated PML bodies by p53/p21 requires HP1 proteins. J Cell Biol (2009) 1.01
Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer (2010) 0.96
Assessing telomeric DNA content in pediatric cancers using whole-genome sequencing data. Genome Biol (2012) 0.95
PML body meets telomere: the beginning of an ALTernate ending? Nucleus (2012) 0.94
Human telomerase activity regulation. Mol Biol Rep (2010) 0.94
Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres. Am J Pathol (2010) 0.93
Telomerase- and Rad52-independent immortalization of budding yeast by an inherited-long-telomere pathway of telomeric repeat amplification. Mol Cell Biol (2008) 0.93
Protein tyrosine phosphatases in glioma biology. Acta Neuropathol (2009) 0.92
PML bodies provide an important platform for the maintenance of telomeric chromatin integrity in embryonic stem cells. Nucleic Acids Res (2013) 0.92
Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res (2012) 0.92
The role of post-translational modifications in fine-tuning BLM helicase function during DNA repair. DNA Repair (Amst) (2014) 0.91
Regulation of telomere length in Drosophila. Cytogenet Genome Res (2009) 0.91
TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression. Neoplasia (2010) 0.90
Modeling human endothelial cell transformation in vascular neoplasias. Dis Model Mech (2013) 0.89
Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol (2012) 0.89
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival. PLoS One (2011) 0.88
Telomere regulation in pluripotent stem cells. Protein Cell (2014) 0.86
Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. J Clin Endocrinol Metab (2014) 0.86
HP1-mediated formation of alternative lengthening of telomeres-associated PML bodies requires HIRA but not ASF1a. PLoS One (2011) 0.86
Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer (2012) 0.84
Telomere length variation: A potential new telomere biomarker for lung cancer risk. Lung Cancer (2015) 0.82
Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma. Am J Transl Res (2015) 0.82
Telomere length is related to alternative splice patterns of telomerase in thyroid tumors. Am J Pathol (2011) 0.82
Telomere maintenance mechanisms in cancer: clinical implications. Curr Pharm Des (2014) 0.82
Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: implications for telomere-based therapies. Am J Pathol (2013) 0.82
ALTernative Telomere Maintenance and Cancer. Trends Cancer (2015) 0.82
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog (2015) 0.81
Modulation of telomeres in alternative lengthening of telomeres type I like human cells by the expression of werner protein and telomerase. J Oncol (2012) 0.80
Genetic Inactivation of ATRX Leads to a Decrease in the Amount of Telomeric Cohesin and Level of Telomere Transcription in Human Glioma Cells. Mol Cell Biol (2015) 0.80
Multiple Mechanisms Contribute To Telomere Maintenance. J Cancer Biol Res (2013) 0.80
Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol (2015) 0.80
Alternative mechanisms of telomere lengthening: permissive mutations, DNA repair proteins and tumorigenic progression. Mutat Res (2012) 0.80
A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT). Int J Cancer (2014) 0.80
Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas. Mod Pathol (2015) 0.80
Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres. Mol Cancer Ther (2010) 0.79
Extreme telomere length dimorphism in the Tasmanian devil and related marsupials suggests parental control of telomere length. PLoS One (2012) 0.79
Visualization of Telomere Integrity and Function In Vitro and In Vivo Using Immunofluorescence Techniques. Curr Protoc Cytom (2015) 0.79
Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol (2012) 0.78
Telomere profiles and tumor-associated macrophages with different immune signatures affect prognosis in glioblastoma. Mod Pathol (2016) 0.77
Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas. J Exp Clin Cancer Res (2008) 0.77
Strong association between long and heterogeneous telomere length in blood lymphocytes and bladder cancer risk in Egyptian. Carcinogenesis (2015) 0.77
Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors. Acta Neuropathol (2013) 0.77
Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas. Int J Clin Exp Pathol (2015) 0.76
Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade. Transl Pediatr (2015) 0.75
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes (Basel) (2016) 0.75
Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. J Pathol Clin Res (2015) 0.75
Expression Pattern of Alternative Splicing Variants of Human Telomerase Reverse Transcriptase (hTERT) in Cancer Cell Lines Was not Associated with the Origin of the Cells. Int J Mol Cell Med (2015) 0.75
Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX. Sci Rep (2016) 0.75
Alternative lengthening of telomeres in primary pancreatic neuroendocrine neoplasms is associated with aggressive clinical behavior and poor survival. Clin Cancer Res (2016) 0.75
The Rb1 tumour suppressor gene modifies telomeric chromatin architecture by regulating TERRA expression. Sci Rep (2017) 0.75
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer. Pharmgenomics Pers Med (2015) 0.75
Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas. Genes (Basel) (2017) 0.75
Key rates for the grades and transformation ability of glioma: model simulations and clinical cases. J Neurooncol (2017) 0.75
Intensive versus conventional glucose control in critically ill patients. N Engl J Med (2009) 26.30
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Hypoglycemia and risk of death in critically ill patients. N Engl J Med (2012) 6.17
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet (2010) 4.26
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab (2005) 4.07
p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85
Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Protein composition of catalytically active human telomerase from immortal cells. Science (2007) 3.53
Alternative lengthening of telomeres in mammalian cells. Oncogene (2002) 3.48
White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury. Stroke (2006) 3.27
Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope (2006) 3.20
Check your cultures! A list of cross-contaminated or misidentified cell lines. Int J Cancer (2010) 3.04
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet (2005) 2.85
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Soft tissue sarcomas. CA Cancer J Clin (2004) 2.65
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer (2003) 2.64
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet (2012) 2.63
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Career satisfaction, practice patterns and burnout among surgical oncologists: report on the quality of life of members of the Society of Surgical Oncology. Ann Surg Oncol (2007) 2.50
Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol (2008) 2.48
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol (2009) 2.35
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res (2004) 2.32
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain (2012) 2.28
Optimizing treatment of desmoid tumors. J Clin Oncol (2007) 2.27
Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol (2002) 2.13
A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery (2011) 2.11
14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09
Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol (2009) 2.08
PI(3)king apart PTEN's role in cancer. Clin Cancer Res (2010) 2.07
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res (2004) 1.99
Angiosarcoma of the breast. Cancer (2005) 1.98
The first molecular details of ALT in human tumor cells. Hum Mol Genet (2005) 1.93
Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head Neck (2002) 1.90
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
High-resolution fiber-optic microendoscopy for in situ cellular imaging. J Vis Exp (2011) 1.88
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J (2009) 1.85
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.82
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol (2012) 1.80
Increasing the pool of academically oriented African-American medical and surgical oncologists. Cancer (2003) 1.77
14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res (2009) 1.74
Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol (2010) 1.73
Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med (2009) 1.72
National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer (2002) 1.71
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg (2002) 1.70
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev (2007) 1.68
Locoregional disease patterns in well-differentiated and dedifferentiated retroperitoneal liposarcoma: implications for the extent of resection? Ann Surg Oncol (2014) 1.67
Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67
Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell (2002) 1.67
Human POT1 facilitates telomere elongation by telomerase. Curr Biol (2003) 1.64
Assaying and investigating Alternative Lengthening of Telomeres activity in human cells and cancers. FEBS Lett (2010) 1.64
Breast cancer metastasis: challenges and opportunities. Cancer Res (2009) 1.63
Bone as a source of FGF23: regulation by phosphate? Bone (2004) 1.63
miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res (2009) 1.62
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab (2013) 1.61
Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust (2005) 1.61
Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients. J Neurochem (2009) 1.61
Molecular pathology and genetic advances in amyotrophic lateral sclerosis: an emerging molecular pathway and the significance of glial pathology. Acta Neuropathol (2011) 1.58
Biopsy of musculoskeletal tumours--beware. ANZ J Surg (2004) 1.56
Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol (2010) 1.56
Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription. Nucleic Acids Res (2009) 1.55
DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology (2009) 1.55
Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem (2007) 1.55
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Spitz naevus versus Spitzoid melanoma: when and how can they be distinguished? Pathology (2002) 1.50
Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet (2005) 1.49
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative. Ann Surg Oncol (2012) 1.48
Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res (2010) 1.47
Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromcytomas and paragangliomas. Clin Endocrinol (Oxf) (2013) 1.46
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep (2011) 1.45
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci (2011) 1.45